[go: up one dir, main page]

BR9915460A - Método de tratamento de febre hemorrágica virótica - Google Patents

Método de tratamento de febre hemorrágica virótica

Info

Publication number
BR9915460A
BR9915460A BR9915460-9A BR9915460A BR9915460A BR 9915460 A BR9915460 A BR 9915460A BR 9915460 A BR9915460 A BR 9915460A BR 9915460 A BR9915460 A BR 9915460A
Authority
BR
Brazil
Prior art keywords
treatment
hemorrhagic fever
viral hemorrhagic
provides
toxicity
Prior art date
Application number
BR9915460-9A
Other languages
English (en)
Inventor
Charles Jack Fisher
Sau-Chi Betty Yan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9915460A publication Critical patent/BR9915460A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Patente de Invenção: <B>"MéTODO DE TRATAMENTO DE FEBRE HEMORRáGICA VIRóTICA"<D>. A presente invenção oferece um método de tratamento de febre hemorrágica virótica com proteína C. A invenção reivindicada oferece uma terapia necessária para um distúrbio sério e debilitante ao mesmo tempo em que evita complicações tais como tendência ao sangramento, toxidez e efeitos secundários comuns dos agentes anticoagulantes atualmente disponíveis.
BR9915460-9A 1998-11-20 1999-11-15 Método de tratamento de febre hemorrágica virótica BR9915460A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10915398P 1998-11-20 1998-11-20
PCT/US1999/027074 WO2000030677A1 (en) 1998-11-20 1999-11-15 Method of treating viral hemorrhagic fever

Publications (1)

Publication Number Publication Date
BR9915460A true BR9915460A (pt) 2001-07-17

Family

ID=22326085

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9915460-9A BR9915460A (pt) 1998-11-20 1999-11-15 Método de tratamento de febre hemorrágica virótica

Country Status (12)

Country Link
US (2) US6270764B1 (pt)
EP (1) EP1131091B1 (pt)
JP (1) JP2002530353A (pt)
CN (1) CN1326356A (pt)
AT (1) ATE235915T1 (pt)
AU (1) AU2149800A (pt)
BR (1) BR9915460A (pt)
CA (1) CA2351470A1 (pt)
DE (1) DE69906568T2 (pt)
ES (1) ES2195655T3 (pt)
IL (1) IL142220A0 (pt)
WO (1) WO2000030677A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2351470A1 (en) * 1998-11-20 2000-06-02 Charles Jack Fisher Method of treating viral hemorrhagic fever
AU2001290553A1 (en) * 2000-09-18 2002-04-02 Eli Lilly And Company Method for using activated protein c for the treatment of coagulation-associated disorders
PL372138A1 (en) 2001-10-15 2005-07-11 Chiron Corporation Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi)
US7132398B2 (en) 2003-05-06 2006-11-07 Dendreon Corporation Method of treatment of hemorrhagic disease using a factor VIIa/tissue factor inhibitor
SG150552A1 (en) * 2004-03-17 2009-03-30 Chiron Corp Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi)
WO2007092607A2 (en) * 2006-02-09 2007-08-16 Genetech, Inc. Treatment of hemorrhagic viral infections using a tissue factor inhibitor
RU2379034C1 (ru) * 2008-11-17 2010-01-20 Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева" Способ лечения геморрагической лихорадки с почечным синдромом
WO2018106250A1 (en) * 2016-12-08 2018-06-14 Cellphire, Inc. Compositions and methods for treatment of loss of fluids leading to hypotension and/or hypovolemia
EP3886879A4 (en) 2018-11-30 2022-12-07 Cellphire Inc. PLATES AS DELIVERY AGENTS
US20200224164A1 (en) 2018-11-30 2020-07-16 Cellphire, Inc. Platelets as delivery agents
CN114072159A (zh) 2019-05-03 2022-02-18 塞尔菲乐有限公司 用于生产血液产品的材料和方法
US20210308185A1 (en) 2020-02-04 2021-10-07 Cellphire, Inc. Methods of treating acquired hemophilia with anti-fibrinolytic loaded platelets
US11701388B2 (en) 2019-08-16 2023-07-18 Cellphire, Inc. Thrombosomes as an antiplatelet agent reversal agent
TW202245814A (zh) 2021-02-17 2022-12-01 美商賽菲爾公司 用於治療抗血小板誘導的凝血病之凍乾血小板衍生物組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US5550036A (en) 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
US4992373A (en) 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
IL97312A (en) 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5506134A (en) * 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
AT402262B (de) 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
CO4940438A1 (es) * 1997-04-28 2000-07-24 Lilly Co Eli Metodos mejorados para el procesamiento de proteina c acti- vada
CA2351470A1 (en) * 1998-11-20 2000-06-02 Charles Jack Fisher Method of treating viral hemorrhagic fever
CA2338799A1 (en) * 1999-04-30 2000-11-09 Eli Lilly And Company Protein c derivatives

Also Published As

Publication number Publication date
CN1326356A (zh) 2001-12-12
US6767539B2 (en) 2004-07-27
EP1131091B1 (en) 2003-04-02
ES2195655T3 (es) 2003-12-01
WO2000030677A1 (en) 2000-06-02
DE69906568T2 (de) 2004-02-12
US20010028880A1 (en) 2001-10-11
DE69906568D1 (de) 2003-05-08
CA2351470A1 (en) 2000-06-02
ATE235915T1 (de) 2003-04-15
AU2149800A (en) 2000-06-13
IL142220A0 (en) 2002-03-10
EP1131091A1 (en) 2001-09-12
JP2002530353A (ja) 2002-09-17
US6270764B1 (en) 2001-08-07

Similar Documents

Publication Publication Date Title
ATE234092T1 (de) 2-alkylpyrrolidine
BR9915460A (pt) Método de tratamento de febre hemorrágica virótica
TR200000782T2 (tr) Resorsinol türevleri.
UA34466C2 (uk) Засіб для несистемної боротьби з паразитуючими комахами
ES2184149T3 (es) Paclitaxeles 6-tio sustituidos.
TR199900083T2 (xx) Klaritromisinin kristal bi�imi I.
PT842934E (pt) Agonistas de 5-ht1f
ATE210988T1 (de) Zytotoxischer aminozucker und verwandte zuckerderivate von indolopyrrolocarbazolen
DK0825857T3 (da) Anvendelse af gabapentin og derivater deraf til behandling af mani og bipolær lidelse
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
EP0318233A3 (en) Improvements in or relating to serotonin and norepinephrine uptake inhibitors
NO990849L (no) Substituerte 1,2,3,4-tetrahydro-2-dibenzofuranaminer og 2-aminocyklohepta (b) benzofuraner
NO993407L (no) Fremstilling av proteinpreparater med nedsatt aggregatinnhold
ID25478A (id) Agonis 5-ht1f
BR9915317A (pt) Método de tratar trombocitopenia induzida por heparina
DK1133314T3 (da) Protein C til behandling af seglcellesygdom og thalassæmi
EP0116628A4 (en) 1-ACYL-3-PYRIDYLMETHYLGUANIDINE AND THEIR USE AS AN ANI-HYPERTENSIVE.
BR9915984A (pt) Método de tratar púrpura trombocitopênica e sìndrome urêmica hemolìtica
ES2061775T3 (es) Derivados de estrobirulina, su obtencion y empleo.
ATE227997T1 (de) Pharmazeutische zusammensetzung zur nasalen verabreichung von thiocolchicosid
PT908107E (pt) Composicoes adocantes contendo neohesperidina-dihidrocalcona e pelo menos um outro adocante de elevada intensidade
IT1271685B (it) Impiego dei polidesossiribonucleotidi nelle neuropati diabetiche
PT1001789E (pt) Produto compreendendo pelo menos um arn de dupla helice em associacao com pelo menos um derivado do 6-benziluracilo para uma utilizacao terapeutica simultanea separada ou prolongada no tempo
UA15363A (uk) Засіб для лікуваhhя відкритих пошкоджеhь
FI954110A0 (fi) Menetelmä (1R,2R)-N-metyyli-2-(3-pyridyyli)-2-tetrahydrotiopyrankarbotiamodi-1-oksidin valmistamiseksi

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]